Vertex Pharmaceuticals Incorporated (VRTX) Q2 2019 Earnings Results

Vertex Pharmaceuticals Beats on EPS, Stock Down 1.72%

Vertex Pharmaceuticals reported a better-than-expected EPS, which indicates strong earnings performance. However, the stock fell by 1.72% following the announcement, suggesting that investors may have been looking for more comprehensive information or guidance that was not provided.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.26	N/A	+13.15%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record for the earnings call, and the analysis is based solely on numerical results.

Vertex Pharmaceuticals Beats on EPS, Stock Down 1.72%

Key numbers

Management commentary

Vertex Pharmaceuticals Incorporated

More earnings this week

Vertex Pharmaceuticals Beats on EPS, Stock Down 1.72%

Key numbers

Management commentary